Novartis AG (NVS)
After hours:
| Previous close | 115.70 |
| Open | 116.30 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's range | 115.60 - 116.63 |
| 52-week range | 92.19 - 120.92 |
| Volume | |
| Avg. volume | 1,235,836 |
| Market cap | 234.791B |
| Beta (5Y monthly) | 0.50 |
| PE ratio (TTM) | 23.72 |
| EPS (TTM) | 4.89 |
| Earnings date | 29 Oct 2024 |
| Forward dividend & yield | 3.78 (3.26%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | 117.31 |
- Yahoo Finance Video
Weight loss drug pricing under fire with pills on the horizon
Senior health reporter Anjalee Khemlani joins Brad Smith and Madison Mills on Catalysts to take a look at pharmaceutical stocks like Novartis (NVS) and Novo Nordisk (NVO) as weight loss drug makers are set to meet with lawmakers like Senator Bernie Sanders to discuss pricing. Khemlani provides insight into the weight loss drug market and pricing in the US compared to other countries around the world. She explains that Pfizer (PFE), Eli Lilly (LLY), and Novo are among the candidates who could offer weight loss drugs in pill form rather than through injection, which could transform the market. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Naomi Buchanan.
ZacksNovartis Wins FDA Approval of Kisqali for Early Breast Cancer
The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.
GlobeNewswireFDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2Kisqali® (ribociclib) significantly reduced the risk of recurrence by 25% vs. endocrine therapy (ET) alone; consistent benefit and a well-tolerated safety profile seen across all subgroups in pivotal Phase III NATALEE trial, including patients with node-negative disease3-6La
